HOME >> BIOLOGY >> NEWS
Enzyme inhibitors block replication of SARS virus

ve been looking at other Liponavir-related compounds for similar blocking effects. During these experiments, they found that a group of catalyzing agents used to help promote chemical reactions in the laboratory were actually more powerful in blocking the SARS protease than either the Lopinavir or any of the target compounds.

These organic compounds are called benzotriazole esters. The esters entered the SARS protease site, formed an intermediary compound, then inactivated the SARS enzyme. The findings were confirmed using mass spectrometry analysis of the enzyme intermediary.

"These benzotriazole esters are relatively stable and act as suicide inhibitors," Wong said. "They block the enzyme, are transformed through a co-valent bond, and are unable to get out."

Wong said the findings published today provide better insight into the mode of action of the enzyme, which may lead to development of a drug against SARS. The findings were made by using rapid drug discovery techniques developed in the Wong lab to screen large numbers of weak enzyme inhibitors, and then attaching additional compounds to look for stronger reactions.

Research Associate Chung-Yi Wu, a member of the Wong lab, is the paper's lead author. He said the finding was unexpected.

"We wanted to improve Liponavir activity," Wu said. "But we found this very surprising and serendipitous result."


'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
28-Mar-2006


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme delivered in smaller package protects cells from radiation damage
3. Enzyme Engineering XIX
4. Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
5. Enzyme shreds Alzheimers protein
6. Enzyme defect leads to hyperinsulinism
7. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
8. Enzyme crystal structure reveals unexpected genome repair functions
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... -- AIC announces that it has just released a new white paper authored by Zettar ... high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... UK (PRWEB) , ... December 08, 2016 , ... ... precision light to control cells — optogenetics — is key to exciting advances ... of the art, spatially patterned light projected via free-space optics stimulates small, transparent ...
(Date:12/8/2016)... England , December 8, 2016 ... has expanded its customisable SureSeq™ NGS panel range with the ... allowing fast and cost-effective study of variants in familial hypercholesterolemia ... number variation (CNV) detection on a single small panel and ... hotspot content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... commercial launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal ... extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
Breaking Biology Technology:
Cached News: